Autoantibodies to angiotensin-converting enzyme 2 in patients with connective tissue diseases
Open Access
- 1 January 2010
- journal article
- Published by Springer Science and Business Media LLC in Arthritis Research & Therapy
- Vol. 12 (3), R85
- https://doi.org/10.1186/ar3012
Abstract
Angiotensin-converting enzyme (ACE) 2, a homolog of ACE, converts angiotensin (Ang) II into Ang(1-7), and the vasoprotective effects of Ang(1-7) have been documented. We explored the hypothesis that serum autoantibodies to ACE2 predispose patients with connective tissue diseases to constrictive vasculopathy, pulmonary arterial hypertension (PAH), or persistent digital ischemia. Serum was examined from 42 patients with systemic lupus erythematosus (SLE), scleroderma, or mixed connective tissue disease. Eighteen vasculopathy patients with PAH (five cases) and/or persistent digital ischemia (16 cases) were compared with 24 patients without these vasculopathies (control patients) for serum reactivity to purified recombinant human ACE2, using an ELISA. The sera from 17 of the 18 (94%) vasculopathy patients had ELISA scores above the baseline level determined using control sera from 28 healthy subjects, and the mean ELISA score in the vasculopathy patients was significantly higher than that in the control patients (P < 0.0005). The relative activity of serum ACE2, which was defined using a reference serum, correlated inversely with the ELISA scores for serum anti-ACE2 antibodies in the 18 vasculopathy patients (R2 = 0.6872). The IgG fraction from vasculopathy patients, but not from healthy subjects, inhibited ACE2 activities in vitro. Consistent with this, immunosuppressive therapy given to one SLE patient with digital necrosis markedly decreased the anti-ACE2 antibody titer and restored serum ACE2 activity. Autoantibodies to ACE2 may be associated with constrictive vasculopathies.Keywords
This publication has 18 references indexed in Scilit:
- Prevention of Pulmonary Hypertension by Angiotensin-Converting Enzyme 2 Gene TransferHypertension, 2009
- Evidence for Angiotensin-converting Enzyme 2 as a Therapeutic Target for the Prevention of Pulmonary HypertensionAmerican Journal of Respiratory and Critical Care Medicine, 2009
- The Vasoactive Peptide Angiotensin-(1–7), Its Receptor Mas and the Angiotensin-converting Enzyme Type 2 are Expressed in the Human EndometriumReproductive Sciences, 2009
- Inhibition of the renin–angiotensin system and target organ protectionHypertension Research, 2009
- Angiotensin-converting enzyme 2: implications for blood pressure and kidney diseaseCurrent Opinion in Nephrology and Hypertension, 2009
- Angiotensin(1-7) Blunts Hypertensive Cardiac Remodeling by a Direct Effect on the HeartCirculation Research, 2008
- Pulmonary capillary endothelial metabolic dysfunction: Severity in pulmonary arterial hypertension related to connective tissue disease versus idiopathic pulmonary arterial hypertensionArthritis & Rheumatism, 2008
- Immunosuppressive therapy in lupus‐ and mixed connective tissue disease–associated pulmonary arterial hypertension: A retrospective analysis of twenty‐three casesArthritis & Rheumatism, 2008
- Raynaud's phenomenon is correlated with elevated systolic pulmonary arterial pressure in patients with systemic lupus erythematosusLupus, 2007
- The 1982 revised criteria for the classification of systemic lupus erythematosusArthritis & Rheumatism, 1982